

**REMARKS**

These remarks are Supplemental to the Response filed October 7, 2003. Applicants thank the Examiner for the interview held February 19, 2004. The amendments to the specification in this Supplemental Response are identical to those made in the Response filed October 7, 2003. Applicants are merely resubmitting the amendments to the specification to conform with the Patent Office's new amendment practice.

**Regarding the Amendments to the Specification**

The specification has been amended to correct several typographical errors. In particular, the specification has been amended at pages 38 and 40 to provide the correct sequences and sequence identifiers for S216, which is "LYRSPSMPENL" and which corresponds to SEQ ID NO:3, and S216A, which is "LYRSPAMPENL" and which corresponds to SEQ ID NO:1897. Support for the amendment to the sequence of S216 as LYRSPSMPENL can be found throughout the specification, for example, at page 21, lines 42-43, which discloses the human Cdc25C sequence, amino acids 211 to 221 (LYRSPSMPENL), from which S216 was derived. Support for the amendment to the sequence of S216A as LYRSPAMPENL can be found, for example, at page 99, Table 2. Thus, as the amendments to correct typographical errors are supported by the specification, no new matter is added and entry thereof is respectfully requested.


### CONCLUSION

If the Examiner would like to discuss any of the issues raised in the Office Action,  
Applicant's representative can be reached at (858) 509-4065.

Please charge any additional fees, or make any credits, to Deposit Account No. 03-3975.

Respectfully submitted,

Date: 2-20-04

  
Robert M. Bedgood, Ph.D.  
Reg. No. 43,488

PILLSBURY WINTHROP LLP  
11682 El Camino Real, Suite 200  
San Diego, CA 92130-2593  
Telephone: (858) 509-4065  
Facsimile: (858) 509-4010